Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay

Analytica Chimica Acta

Volumn 852, Issue , 2014, Pages 212-217

  Chowdhury, Basudev ^a   Cho, Il Hoon ^a,c   Hahn, Noah ^b   Irudayaraj, Joseph ^a  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Eulji University   (South Korea)

Author keywords

5 Carboxylcytosine (5caC); 5 Formylcytosine (5fC); 5 Hydroxymethylcytosine (5hmC); 5 Methylcytosine (5mC); Cancer; Enzyme based Immunoassay (EIA); Epigenetic modifications

Indexed keywords

BIOLOGICAL ORGANS; CHEMICAL DETECTION; DISEASES; ENZYMES; IMMUNOLOGY; MAMMALS; PATIENT MONITORING;

5-CARBOXYLCYTOSINE (5CAC); 5-FORMYLCYTOSINE (5FC); 5-HYDROXYMETHYLCYTOSINE; 5-METHYLCYTOSINE (5MC); CANCER; EPIGENETIC MODIFICATION;

BLOOD;

5 CARBOXYLCYTOSINE; 5 FORMYLCYTOSINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CYTOSINE DERIVATIVE; GENOMIC DNA; HORSERADISH PEROXIDASE; STREPTAVIDIN; UNCLASSIFIED DRUG; 5-CARBOXYLCYTOSINE; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DNA;

ARTICLE; BLADDER CANCER; BLOOD ANALYSIS; CARCINOGENESIS; CONTROLLED STUDY; DNA ISOLATION; ENZYME IMMUNOASSAY; EPIGENETICS; HUMAN; LUNG CANCER; METASTASIS POTENTIAL; NUCLEIC ACID ANALYSIS; PANCREAS CANCER; QUANTITATIVE ANALYSIS; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; GENETIC EPIGENESIS; GENETICS; LIMIT OF DETECTION; NEOPLASM; PROCEDURES; VALIDATION STUDY;

5-METHYLCYTOSINE; CYTOSINE; DNA; EPIGENESIS, GENETIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIMIT OF DETECTION; NEOPLASMS;

EID: 84912527399     PISSN: 00032670     EISSN: 18734324     Source Type: Journal    
DOI: 10.1016/j.aca.2014.09.020     Document Type: Article

References (52)

1. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 2008, 9:465-476.
2. Laird P.W. Principles and challenges of genome-wide DNA methylation analysis. Nat. Rev. Genet. 2010, 11:191-203.
3. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
4. Jones P.A., Taylor S.M. Cellular-differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
5. Ito S., Shen L., Dai Q., et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
6. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
7. Kriaucionis S., Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009, 324:929-930.
8. He Y.F., Li B.Z., Li Z., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
9. Haffner M.C., Chaux A., Meeker A.K., et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2:627-637.
10. Li W., Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J. nucleic acids 2011, 2011:870726.
11. Moran-Crusio K., Reavie L., Shih A., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
12. Kellinger M.W., Song C.X., Chong J., Lu X.Y., He C., Wang D. 5-formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nat. Struct. Mol. Biol. 2012, 19:831-833.
13. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Nat. Cancer Inst. 2000, 92:564-569.
14. Friedrich M.G., Weisenberger D.J., Cheng J.C., et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 2004, 10:7457-7465.
15. Palmisano W.A., Divine K.K., Saccomanno G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000, 60:5954-5958.
16. Mulero-Navarro S., Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 2008, 68:1-11.
17. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
18. Gamasosa M.A., Slagel V.A., Trewyn R.W., et al. The 5-methylcytosine content of DNA from human-tumors. Nucleic Acids Res. 1983, 11:6883-6894.
19. De Smet C., Loriot A. DNA hypomethylation in cancer epigenetic scars of a neoplastic journey. Epigenetics 2010, 5:8.
20. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2014, 17:330-339.
21. Kumar S., Mohan A., Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers 2006, 11:385-405.
22. Liggett T., Melnikov A., Yi Q.-L., et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 1674-1680, 116.
23. Tao L.H., Wang W., Kramer P.M., Lubet R.A., Steele V.E., Pereira M.A. Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention of colon cancer. Mol. Carcinog. 2004, 39:79-84.
24. Tsou J.A., Hagen J.A., Carpenter C.L., Laird-Offringa I.A. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002, 21:5450-5461.
25. Yang H., Liu Y., Bai F., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669.
26. Kohli R.M., Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 2013, 502:472-479.
27. Song C.-X., He C. Potential functional roles of DNA demethylation intermediates. Trends Biochem. Sci. 2013, 38:480-484.
28. Song C.-X., He C. Balance of DNA methylation and demethylation in cancer development. Genome Biol. 2012, 13.
29. Thuc L., Kim K.-P., Fan G., Faull K.F. A sensitive mass spectrometry method for simultaneous quantification of DNA methylation and hydroxymethylation levels in biological samples. Anal. Biochem. 2011, 412:203-209.
30. Shen L., Waterland R.A. Methods of DNA methylation analysis. Curr. Opin. Clin. Nutr. Metabol. Care 2007, 10:576-581.
31. Gupta R., Nagarajan A., Wajapeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques 2010, 49:III-XI.
32. Leng S.X., McElhaney J.E., Walston J.D., Xie D., Fedarko N.S., Kuchel G.A. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. Series A Biol. Sci. Med. Sci. 2008, 63:879-884.
33. Inc. EG, MethylFlash Hydroxymethylated DNA Quantification Kit (Colorimetric), Retrieved 04.16.2014 from . http://www.epigentek.com/catalog/methylflash-hydroxymethylated-dna-quantification-kit-colorimetric-p-1858.html.
34. Inc. EG, MethylFlash Methylated DNA Quantification Kit (Colorimetric), Retrieved 04.16.2014 from . http://www.epigentek.com/catalog/methylflash-methylated-dna-quantification-kit-colorimetric-p-2094.html.
35. Cell Biolabs I, Global DNA Methylation ELISA, Retrieved 04.16.2014 from . http://www.cellbiolabs.com/global-dna-methylation-elisa.
36. Janolino V.G., Fontecha J., Swaisgood H.E. A spectrophotometric assay for biotin-binding sites of immobilized avidin. Appl. Biochem. Biotechnol. 1996, 56:1-7.
37. Cho I.-H., Paek E.-H., Kim Y.-K., Kim J.-H., Paek S.-H. Chemiluminometric enzyme-linked immunosorbent assays (ELISA)-on-a-chip biosensor based on cross-flow chromatography. Anal. Chim. Acta 2009, 632:247-255.
38. Miller J.C., Miller J.N. Basic statistical-methods for analytical-chemistry. 1. Statistics of repeated measurements - a review. Analyst 1988, 113:1351-1356.
39. Brady T.C., Yang T.J., Hyde W.G., Kind A.J., Hill D.W. Detection of flunixin in greyhound urine by a kinetic enzyme-linked immunosorbent assay. J. Anal. Toxicol. 1997, 21:190-196.
40. Hayashi Y., Matsuda R., Maitani T., et al. Precision, limit of detection and range of quantitation in competitive ELISA. Anal. Chem. 2004, 76:1295-1301.
41. Liu C.C., Ou T.T., Wu C.C., et al. Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus 2011, 20:131-136.
42. Jin S.-G., Jiang Y., Qiu R., et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res. 2011, 71:7360-7365.
43. Konstandin N., Bultmann S., Szwagierczak A., et al. Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 2011, 25:1649-1652.
44. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2014, 468:839-843.
45. Tahara T., Maegawa S., Chung W., et al. Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev. Res. 2013, 6:1093-1100.
46. Hsiung D.T., Marsit C.J., Houseman E.A., et al. Global DNA. methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2007, 16:108-114.
47. Barnard D.L., Johnson F.B., Richards D.F. Comparison of an avidin-biotin immunoassay with 3 commercially available immunofluorescence kits for typing of herpes-simplex virus. J. Clin. Pathol. 1985, 38:1158-1162.
48. Inc. EG, DNA. Methylation Quantification, Retrieved 04.16.2014 from . http://www.epigentek.com/catalog/dna-methylation-quantification-c-75_21_48.html.
49. ACS Cancer Facts and Figures 2013 2013, 60. American Cancer Sociery, Atlanta.
50. DeWoskin V.A., Million R.P. The epigenetics pipeline. Nat. Rev. Drug Discov. 2013, 12:661-662.
51. Singh V., Sharma P., Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr. Cancer Drug Targets 2013, 13:379-399.
52. Shen L., Zhang Y. Enzymatic analysis of Tet proteins: key enzymes in the metabolism of DNA methylation. Methods in Enzymol. 2012, 512:93-105.